Summary
A prospective randomized trial was conducted comparing the clinical response of 60 patients with advanced breast cancer to a combination of adriamycin, cyclophosphamide, and oral ftorafur (ACF), or to a combination of ACF plus methotrexate (ACFM). The response rate was 12 of 28 (43%) in ACF and 18 of 30 (60%) in ACFM. Responses were seen more frequently in patients in whom fewer than two organs were involved, and responses at dominant metastatic sites were equal for the two arms. The response duration was 21+ (3.5–49.5+) months with ACF, as against 6.9 (1.9–30.8+) months with ACFM (P<0.05). The median survival time from start of therapy was 20.8+ months for ACF, while that for ACFM was 13+ months (statistically not significant). The major toxicities were hair loss, GI toxicity, and leukopenia. The response rate with ACFM was higher than that with ACF, but the addition of methotrexate to ACF did not increase the complete response rate or prolong response duration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bull JM, Tormey DC, Li S, Carbone PP, Falkson G, Blom J, Perlin E, Simon R (1978) A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41: 1949
Carter SK (1974) The chemical therapy of breast cancer. Semin Oncol 1: 131
Cooper RG, (1969) Combination chemotherapy in hormone resistant breast cancer. Proc Am Assoc Cancer Res 10: 15
Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD (1977) Assessment of response to therapy in advanced breast cancer. Eur J Cancer 13: 89
Hortobagyi GN, Gutterman JU, Blumenschein GR, Tashima CK, Burgess MA, Einhorn L, Buzdar AU, Richman SP, Hersh EM (1979a) Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. Cancer 43: 1225
Hortobagyi GN, Blumenschein GR, Tashima CK, Buzdar AU, Burgess MA, Livingston RB, Valdivieso M, Gutterman JU, Hersh EM, Bodey GP (1979b) Ftorafur, adriamycin, cyclophosphamide and BCG in the treatment of metastatic breast cancer. Cancer 44: 398
Inagaki J, Horikoshi N, Ezaki K, Inoue K, Okabe K, Aiba K, Domyo M, Nagata T, Ogawa M (1981) Adriamycin, cyclophosphamide, and ftorafur combination chemotherapy for advanced breast cancer. In: Current chemotherapy and immunotherapy. Proceedings of the 12th International Congress of Chemotherapy. American Society for Microbiology, Washington, p 1484
Konda C (1975) The effect of oral and rectal administration of N-(2-Tetrahydrofuryl)-5-Fluorouracil in the treatment of advanced cancer. Jpn J Cancer Clin 21: 1044
Kuno K, Fukami A (1979) Cancer of the breast at Cancer Institute Hospital. Tokyo: In: Recent results of cancer treatment in Japan. Japan Scientific Societies Press, Tokyo, p 159, Gann monograph on cancer research, no 22
Smalley RV, Carpenter J, Bartolucci A, Vogel C, Krauss S (1977) A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A Southeastern Cancer Study Group Project. Cancer 40: 625
Tranum B, Hoogstraten B, Kennedy A, Vaughin CB, Samal B, Thigpen T, Rivkin S, Smith F, Palmer RL, Costanzi J, Tucker WG, Wilson H, Maloney TR (1978) Adriamycin in combination for the treatment of breast cancer. A Southwest Oncology Group Study. Cancer 41: 2078
Young RC, Lippmann M, DeVita VT, Bull J, Tormey D (1977) NIH conference: Perspectives in the treatment of breast cancer: 1976. Ann Intern Med 86: 784
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Inoue, K., Ogawa, M., Inagaki, J. et al. A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer. Cancer Chemother. Pharmacol. 13, 95–99 (1984). https://doi.org/10.1007/BF00257122
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00257122